Piper Sandler raised the firm’s price target on Halozyme (HALO) to $52 from $51 and keeps a Neutral rating on the shares. The firm notes reported Q3 earnings with both a solid top- and bottom-line beat.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HALO:
- Halozyme price target raised to $68 from $65 at H.C. Wainwright
- Halozyme price target raised to $73 from $72 at JMP Securities
- Halozyme Therapeutics Reports Strong Q3 2024 Results
- Closing Bell Movers: Amazon gains 6%, Apple slips 2% on earnings
- Halozyme raises FY24 non-GAAP EPS view to $4.00-$4.20 from $3.65-$4.05